Lords Mark Microbiotech Pvt. Ltd., a subsidiary of Lords Mark Industries Limited, has received accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL), a recognised validation that places the company among India's established diagnostic providers. This distinction reflects the organisation's focus on testing accuracy, reporting excellence, and patient trust.
Building on this milestone, the company has outlined a nationwide expansion blueprint to establish 200 laboratories and 2,000 collection centres within the next two years, positioning itself to become one of the top five organised pathology players in the country. The existing network of 12 laboratories and 68 collection centres forms the backbone of this scale-up, supported by instrumentation expertise and integration of routine pathology and genomic screening under one ecosystem.
A key innovation supporting differentiation is the company’s customised Organ Health Score, an intelligent health evaluation model that provides personalised direction for early detection and preventive action marking a shift from episodic diagnosis to continuous, proactive health management.
Speaking on the accreditation and strategic vision, Subodh Gupta, CEO, Lords Mark Microbiotech Pvt. Ltd., said:“NABL accreditation is a defining achievement for us, symbolising our steadfast commitment to precision, quality, and trust. It strengthens our mission to make advanced diagnostics and genomic intelligence the foundation of preventive healthcare in India. Our focus is not merely on expanding infrastructure, but on reshaping access, enabling early intervention, and empowering individuals with personalised health insights. The future of diagnostics truly begins here at Lords Mark Microbiotech.”
With quality validation at its core and an expansion strategy built around accessibility, Lords Mark Microbiotech aims to contribute to India’s transition toward a more accessible, technology-enabled, preventive healthcare ecosystem, where disease prevention becomes the norm, not the exception.
{{/usCountry}}With quality validation at its core and an expansion strategy built around accessibility, Lords Mark Microbiotech aims to contribute to India’s transition toward a more accessible, technology-enabled, preventive healthcare ecosystem, where disease prevention becomes the norm, not the exception.
{{/usCountry}}https://mydna.lordsmicrobiotech.com/
Note to the Reader: This article is part of Hindustan Times' promotional consumer connect initiative and is independently created by the brand. Hindustan Times assumes no editorial responsibility for the content.